Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus are the major causes of significant mortality and morbidity. NAFLD and type 2 diabetes have common risk factors. SGLT-2 inhibitors are believed to have a beneficial effect on liver fat in patients with NAFLD and type 2 diabetes. However, there are limited data available on this aspect of empagliflozin use. Thus, we aimed to compare the impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD. METHODS: A comprehensive search of databases like PubMed, Google Scholar, and Cochrane Library was done. In the end, a detailed analysis was performed on a total of 6 finalized studies, all of which were randomized controlled trials. This comprehensive analysis consisted of a cohort of 589 Individuals. RESULTS: A total of six studies were included. Primary outcomes assessed were MRI-PDFF, AST, ALT, HOMA-IR and total bilirubin. Empagliflozin significantly reduced liver fat compared to placebo, with a pooled standardized mean difference (SMD) of −0.43 (95% CI: −0.82 to −0.04; p = 0.03; I² = 0%). AST also showed a significant reduction (SMD = −0.41; 95% CI: −0.66 to −0.16; p = 0.001; I² = 34%), while ALT showed a non-significant trend favoring empagliflozin (SMD = −0.60; 95% CI: −1.25 to 0.04; p = 0.07) with high heterogeneity (I² = 91%). No significant effects were observed for HOMA-IR (SMD = −0.10; 95% CI: −0.43 to 0.24; p = 0.57) or total bilirubin (SMD = −0.04; 95% CI: −1.16 to 1.08; p…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 589 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.